137 related articles for article (PubMed ID: 7819582)
1. Immunohistochemical studies of early breast cancer evolution.
Allred DC; O'Connell P; Fuqua SA; Osborne CK
Breast Cancer Res Treat; 1994; 32(1):13-8. PubMed ID: 7819582
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in early breast neoplasia.
Allred DC; O'Connell P; Fuqua SA
J Cell Biochem Suppl; 1993; 17G():125-31. PubMed ID: 8007690
[TBL] [Abstract][Full Text] [Related]
3. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
4. Molecular genetic studies of early breast cancer evolution.
O'Connell P; Pekkel V; Fuqua S; Osborne CK; Allred DC
Breast Cancer Res Treat; 1994; 32(1):5-12. PubMed ID: 7819586
[TBL] [Abstract][Full Text] [Related]
5. Retinoic acid receptor and retinoid X receptor in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Sasano H
Jpn J Cancer Res; 2000 Nov; 91(11):1169-76. PubMed ID: 11092983
[TBL] [Abstract][Full Text] [Related]
6. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
7. The timing and characterization of p53 mutations in progression from atypical ductal hyperplasia to invasive lesions in the breast cancer.
Kang JH; Kim SJ; Noh DY; Choe KJ; Lee ES; Kang HS
J Mol Med (Berl); 2001 Nov; 79(11):648-55. PubMed ID: 11715068
[TBL] [Abstract][Full Text] [Related]
8. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
10. Timing of critical genetic changes in human breast disease.
Ellsworth RE; Ellsworth DL; Deyarmin B; Hoffman LR; Love B; Hooke JA; Shriver CD
Ann Surg Oncol; 2005 Dec; 12(12):1054-60. PubMed ID: 16228814
[TBL] [Abstract][Full Text] [Related]
11. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
12. Genetic alterations in presumptive precursor lesions of breast carcinomas.
Aubele M; Werner M; Höfler H
Anal Cell Pathol; 2002; 24(2-3):69-76. PubMed ID: 12446956
[TBL] [Abstract][Full Text] [Related]
13. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci.
O'Connell P; Pekkel V; Fuqua SA; Osborne CK; Clark GM; Allred DC
J Natl Cancer Inst; 1998 May; 90(9):697-703. PubMed ID: 9586667
[TBL] [Abstract][Full Text] [Related]
14. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
15. What's new in breast cancer? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease.
Dawkins HJ; Robbins PD; Smith KL; Sarna M; Harvey JM; Sterrett GF; Papadimitriou JM
Pathol Res Pract; 1993 Dec; 189(10):1233-52. PubMed ID: 7910395
[TBL] [Abstract][Full Text] [Related]
16. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
17. HER2 as a prognostic factor in breast cancer.
Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
19. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
[TBL] [Abstract][Full Text] [Related]
20. Nuclear cytometric changes in breast carcinogenesis.
Mommers EC; Poulin N; Sangulin J; Meijer CJ; Baak JP; van Diest PJ
J Pathol; 2001 Jan; 193(1):33-9. PubMed ID: 11169513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]